AbbVie Inc. (ABBV) — Stock Price, Financials & Analysis

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Key Statistics — ABBV

  • Latest Close: $250.09
  • Market Cap: $441.94B
  • P/E Ratio (TTM): 70.4
  • EPS (TTM): $3.55
  • Dividend Yield: 279.00%
  • Beta: 0.28
  • 52-Week High: $267.47
  • 52-Week Low: $190.75
  • Profit Margin: 9.8%

Sector: Healthcare — Drug Manufacturers - General

Income Statement — ABBV

  • 2022: Revenue $58.05B, Net Income $11.84B
  • 2023: Revenue $54.32B, Net Income $4.86B
  • 2024: Revenue $56.33B, Net Income $4.28B
  • 2025: Revenue $61.16B, Net Income $4.23B
“”Wednesday, August 12, 2026
Minimaxmax⁡x∈Δmin⁡y∈Δ x⊤ ⁣A y=v∗\max_{x \in \Delta} \min_{y \in \Delta} \, x^\top\! A \, y = v^*maxx∈Δ​miny∈Δ​x⊤Ay=v∗§Zero-Sum∑i=1nui(s)=0    ∀ s∈S\textstyle\sum_{i=1}^{n} u_i(s) = 0 \;\; \forall \, s \in S∑i=1n​ui​(s)=0∀s∈S§Nash Eq.x∗⊤ ⁣Ay≥x∗⊤ ⁣Ay∗≥x⊤ ⁣Ay∗x^{*\top}\! A y \geq x^{*\top}\! A y^* \geq x^\top\! A y^*x∗⊤Ay≥x∗⊤Ay∗≥x⊤Ay∗§ExpectedE[u1]=x⊤ ⁣A y\mathbb{E}[u_1] = x^\top\! A \, yE[u1​]=x⊤Ay§RegretRT=max⁡i∑t=1Tuit−∑t=1TuattR_T = \max_i \sum_{t=1}^{T} u_i^t - \sum_{t=1}^{T} u_{a_t}^tRT​=maxi​∑t=1T​uit​−∑t=1T​uat​t​§LP Dualmin⁡y,ww    s.t.    Ay≤w⋅1\min_{y,w} w \;\; \text{s.t.} \;\; Ay \leq w \cdot \mathbf{1}miny,w​ws.t.Ay≤w⋅1§Payoffu1(i,j)=aij,    u2(i,j)=−aiju_1(i,j) = a_{ij}, \;\; u_2(i,j) = -a_{ij}u1​(i,j)=aij​,u2​(i,j)=−aij​§Minimaxmax⁡x∈Δmin⁡y∈Δ x⊤ ⁣A y=v∗\max_{x \in \Delta} \min_{y \in \Delta} \, x^\top\! A \, y = v^*maxx∈Δ​miny∈Δ​x⊤Ay=v∗§Zero-Sum∑i=1nui(s)=0    ∀ s∈S\textstyle\sum_{i=1}^{n} u_i(s) = 0 \;\; \forall \, s \in S∑i=1n​ui​(s)=0∀s∈S§Nash Eq.x∗⊤ ⁣Ay≥x∗⊤ ⁣Ay∗≥x⊤ ⁣Ay∗x^{*\top}\! A y \geq x^{*\top}\! A y^* \geq x^\top\! A y^*x∗⊤Ay≥x∗⊤Ay∗≥x⊤Ay∗§ExpectedE[u1]=x⊤ ⁣A y\mathbb{E}[u_1] = x^\top\! A \, yE[u1​]=x⊤Ay
0∑×$0 sometimesAlpha v0.1.0

The Shounya

HomeScreenerHeatmapSectorsDividendsCompareWatchlistPortfolioChartTechnicalScannerEarningsCorrelationSector AnalysisInsidersCongressNewsLearnAboutStatus
← Home← ScreenerChart TerminalTechnical
ABBVHealthcare

AbbVie Inc. — Healthcare · Drug Manufacturers - General

$250.09+2.12 (+0.85%)
Mkt Cap
$441.94B
P/E
70.4
EPS
$3.55
Beta
0.28
Yield
279.00%
52W Hi
$267.47
52W Lo
$190.75
Vol
6.8M

Price History

Chart Terminal →Technical Analysis →

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
57,000
HQ
North Chicago, IL, United States
Web
abbvie.com

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Top Executives

NameTitleTotal Pay
Mr. Robert A. Michael CPACEO & Chairman of the Board$7.4M
Mr. Scott T. ReentsExecutive VP & CFO$3.9M
Dr. Azita Saleki Ph.D.Executive VP & COO$4.1M
Dr. Roopal B. Thakkar M.D.Executive VP of Research & Development and Chief Scientific Officer$3.6M
Mr. Jeffrey Ryan StewartExecutive VP & Chief Commercial Officer$5.0M
Ms. Linda RaySenior VP & Chief Information Officer—
Ms. Elizabeth SheaSenior Vice President of Investor Relations—
Mr. Perry C. SiatisExecutive VP, General Counsel & Secretary—
Mr. Demetris D. CrumExecutive VP & Chief Human Resources Officer—
Mr. Wulff-Erik von BorckeSenior VP & President of Oncology—

Financial Statements

✓
Profitable
All 4 periods
✓
Revenue Growing
+8.6% latest, 2/3 up
✗
Earnings Growing
-1.2% latest, 0/3 up
✗
Pays Dividend
No dividends
✓
Positive Margin
9.8% net margin

AbbVie Inc.

Healthcare \u00b7 Drug Manufacturers - General

Market Cap$441.94B
Trailing P/E70.4
Forward P/E15.4
EPS (trailing)$3.55
EPS (forward)$16.28
Gross Margin72.8%
Operating Margin40.0%
Profit Margin9.8%
Dividend Rate$6.92/share
Dividend Yield279.0%
Payout Ratio190.4%

Revenue & Net Income

2022 – 2025, Annual

Revenue

Net Income

Profit Margins

2022 – 2025, Annual

Earnings Per Share

2022 – 2025, Annual

Dividends

No dividend history available.

Price Ranges

52-Week
$190.75$267.47
Fwd P/E15.4
Avg Volume6.8M
Shares Out1.77B

Key Ratios

Gross Margin72.8%
Operating Margin40.0%
Profit Margin9.8%
ROEN/A
ROA10.5%
P/B-74.5
D/EN/A
Current Ratio0.81
Dividend Rate$6.92
Payout Ratio190.4%

Cash & Debt

Cash 8%Debt 92%
Total Cash$6.57B
Total Debt$70.88B
Net Cash$-64.32B
Free Cash Flow$16.87B
Operating CF$19.51B

Ratings Snapshot

3.0 / 5
P/E1/5(70.4)
P/B5/5(-74.5)
ROE3/5
ROA4/5(10.5)
D/E3/5
Liquidity2/5(0.8)

Growth Pulse

Revenue Growth+10.2%
Earnings Growth+290.4%

Analyst Recommendations

0m
Buy (31 analysts)
8
16
6
Strong Buy: 8
Buy: 16
Hold: 6
Sell: 0
Strong Sell: 1
MonthStr BuyBuyHoldSellStr Sell
0m816601
-1m816601
-2m816601
-3m816800

Income Snapshot 2025

Revenue
$61.2B
Net Income
$4.2B
Gross Margin
70.2%
Net Margin
6.9%
Op. Income
$20.1B
EPS
$2.37

Balance Sheet

2021 – 2025, Annual
Current Ratio0.67x
May struggle to pay near-term bills
Net Debt$62.27B
Total debt minus cash on hand

Assets vs Liabilities vs Equity

Assets = Liabilities + Equity. The green bar is what's left for shareholders after paying all debts.

Cash vs Debt

How much cash the company has on hand vs how much it owes in total debt.

Period Detail

PeriodAssetsLiabilitiesEquityCashDebtD/E
2021N/AN/AN/AN/AN/A—
2022$138.81B$121.52B$17.25B$9.20B$63.27B3.67x
2023$134.71B$124.31B$10.36B$12.81B$59.38B5.73x
2024$135.16B$131.80B$3.33B$5.52B$67.14B20.19x
2025$133.96B$137.19B$-3.27B$5.23B$67.50B—

Balance Sheet Snapshot 2025

Total Assets$133.96B
Total Liabilities$137.19B
Equity$-3.27B
Retained Earnings$-15.49B
Goodwill$35.64B
Long-Term Debt$58.94B

Cash Flow Statement

2021 – 2025, Annual

Operating · Investing · Financing

Operating — cash from core business.Investing — buying/selling long-term assets.Financing — debt, equity & dividends.

Free Cash Flow

Operating cash flow minus capital expenditure — the cash available after maintaining operations.

PeriodOperatingInvestingFinancingFCFCapEx
2021$0$0$0$0$0
2022$25B$-623M$-25B$24B$-695M
2023$23B$-2B$-17B$22B$-777M
2024$19B$-21B$-5B$18B$-974M
2025$19B$-7B$-13B$18B$-1B

Capital Allocation 2025

CapEx$1.21B
Dividends Paid$11.66B
Buybacks$980.0M
Debt Repaid$9.60B
Debt Issued$9.29B
Net Change Cash$-337.0M

Price History

Chart Terminal →Technical Analysis →

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
57,000
HQ
North Chicago, IL, United States
Web
abbvie.com

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Top Executives

NameTitleTotal Pay
Mr. Robert A. Michael CPACEO & Chairman of the Board$7.4M
Mr. Scott T. ReentsExecutive VP & CFO$3.9M
Dr. Azita Saleki Ph.D.Executive VP & COO$4.1M
Dr. Roopal B. Thakkar M.D.Executive VP of Research & Development and Chief Scientific Officer$3.6M
Mr. Jeffrey Ryan StewartExecutive VP & Chief Commercial Officer$5.0M
Ms. Linda RaySenior VP & Chief Information Officer—
Ms. Elizabeth SheaSenior Vice President of Investor Relations—
Mr. Perry C. SiatisExecutive VP, General Counsel & Secretary—
Mr. Demetris D. CrumExecutive VP & Chief Human Resources Officer—
Mr. Wulff-Erik von BorckeSenior VP & President of Oncology—

Price Ranges

52-Week
$190.75$267.47
Fwd P/E15.4
Avg Volume6.8M
Shares Out1.77B

Key Ratios

Gross Margin72.8%
Operating Margin40.0%
Profit Margin9.8%
ROEN/A
ROA10.5%
P/B-74.5
D/EN/A
Current Ratio0.81
Dividend Rate$6.92
Payout Ratio190.4%

Cash & Debt

Cash 8%Debt 92%
Total Cash$6.57B
Total Debt$70.88B
Net Cash$-64.32B
Free Cash Flow$16.87B
Operating CF$19.51B

Ratings Snapshot

3.0 / 5
P/E1/5(70.4)
P/B5/5(-74.5)
ROE3/5
ROA4/5(10.5)
D/E3/5
Liquidity2/5(0.8)

Growth Pulse

Revenue Growth+10.2%
Earnings Growth+290.4%

Analyst Recommendations

0m
Buy (31 analysts)
8
16
6
Strong Buy: 8
Buy: 16
Hold: 6
Sell: 0
Strong Sell: 1
MonthStr BuyBuyHoldSellStr Sell
0m816601
-1m816601
-2m816601
-3m816800

Financial Statements

✓
Profitable
All 4 periods
✓
Revenue Growing
+8.6% latest, 2/3 up
✗
Earnings Growing
-1.2% latest, 0/3 up
✗
Pays Dividend
No dividends
✓
Positive Margin
9.8% net margin

AbbVie Inc.

Healthcare \u00b7 Drug Manufacturers - General

Market Cap$441.94B
Trailing P/E70.4
Forward P/E15.4
EPS (trailing)$3.55
EPS (forward)$16.28
Gross Margin72.8%
Operating Margin40.0%
Profit Margin9.8%
Dividend Rate$6.92/share
Dividend Yield279.0%
Payout Ratio190.4%

Revenue & Net Income

2022 – 2025, Annual

Revenue

Net Income

Profit Margins

2022 – 2025, Annual

Earnings Per Share

2022 – 2025, Annual

Dividends

No dividend history available.

Income Snapshot 2025

Revenue
$61.2B
Net Income
$4.2B
Gross Margin
70.2%
Net Margin
6.9%
Op. Income
$20.1B
EPS
$2.37

Balance Sheet

2021 – 2025, Annual
Current Ratio0.67x
May struggle to pay near-term bills
Net Debt$62.27B
Total debt minus cash on hand

Assets vs Liabilities vs Equity

Assets = Liabilities + Equity. The green bar is what's left for shareholders after paying all debts.

Cash vs Debt

How much cash the company has on hand vs how much it owes in total debt.

Period Detail

PeriodAssetsLiabilitiesEquityCashDebtD/E
2021N/AN/AN/AN/AN/A—
2022$138.81B$121.52B$17.25B$9.20B$63.27B3.67x
2023$134.71B$124.31B$10.36B$12.81B$59.38B5.73x
2024$135.16B$131.80B$3.33B$5.52B$67.14B20.19x
2025$133.96B$137.19B$-3.27B$5.23B$67.50B—

Balance Sheet Snapshot 2025

Total Assets$133.96B
Total Liabilities$137.19B
Equity$-3.27B
Retained Earnings$-15.49B
Goodwill$35.64B
Long-Term Debt$58.94B

Cash Flow Statement

2021 – 2025, Annual

Operating · Investing · Financing

Operating — cash from core business.Investing — buying/selling long-term assets.Financing — debt, equity & dividends.

Free Cash Flow

Operating cash flow minus capital expenditure — the cash available after maintaining operations.

PeriodOperatingInvestingFinancingFCFCapEx
2021$0$0$0$0$0
2022$25B$-623M$-25B$24B$-695M
2023$23B$-2B$-17B$22B$-777M
2024$19B$-21B$-5B$18B$-974M
2025$19B$-7B$-13B$18B$-1B

Capital Allocation 2025

CapEx$1.21B
Dividends Paid$11.66B
Buybacks$980.0M
Debt Repaid$9.60B
Debt Issued$9.29B
Net Change Cash$-337.0M
0∑×

Free market data & analysis tools.

Markets
HomeScreenerHeatmapSectorsEarnings
Tools
WatchlistCompareChart TerminalTechnical
Research
CongressInsidersDividendsCorrelation
© 2026 ShounyaAlpha v0.1.0Not financial advice · hanabira.org